Literature DB >> 30249877

Pyruvate kinase M2 inhibits the progression of bladder cancer by targeting MAKP pathway.

Qiang Zhu1, Baofa Hong1, Lei Zhang1, Jing Wang1.   

Abstract

PURPOSE: Pyruvate kinase M2 (PKM2) was found overexpressed in tumor cells and played a significant role in tumor formation and growth. We sought to explore the correlation of PKM2 expression with cell proliferation, invasion, and apoptosis in bladder cancer cell line.
MATERIALS AND METHODS: Real-time polymerase chain reaction and Western blot were performed to determine the expression level of PKM2 at mRNA and protein level. MTT and flow cytometry were respectively used to explore the proliferation, invasion, and apoptosis in bladder cancer cell line in vitro.
RESULTS: The results suggested that suppression of PKM2 significantly decreased the proliferation rate, invasive cell number, and migration ability of bladder cancer cells compared with blank group. Moreover, proteins such as MMP2 and MMP9 as well as P38 expression were also affected by the PKM2 expression changes. These results proved that PKM2 could be involved in the progression of bladder cancer by mitogen-activated protein kinases signaling pathway.
CONCLUSION: The data presented in this study revealed that PKM2 up-regulation may promote the development and metastasis of bladder cancer through promoting cell proliferation, migration and invasion via MAPK signal pathway.

Entities:  

Keywords:  Bladder cancer; cell invasion; cell proliferation; mitogen-activated protein kinases pathway; pyruvate kinase M2

Mesh:

Substances:

Year:  2018        PMID: 30249877     DOI: 10.4103/0973-1482.187302

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  5 in total

1.  PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma.

Authors:  Zhi Yu; Dan Wang; Yingying Tang
Journal:  Mol Cell Biochem       Date:  2021-01-29       Impact factor: 3.396

2.  The role of the HIF-1α/ALYREF/PKM2 axis in glycolysis and tumorigenesis of bladder cancer.

Authors:  Jing-Zi Wang; Wei Zhu; Jie Han; Xiao Yang; Rui Zhou; Hong-Cheng Lu; Hao Yu; Wen-Bo Yuan; Peng-Chao Li; Jun Tao; Qiang Lu; Ji-Fu Wei; Haiwei Yang
Journal:  Cancer Commun (Lond)       Date:  2021-05-15

3.  Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study.

Authors:  Chara Papadaki; Stavroula Manolakou; Eleni Lagoudaki; Spyros Pontikakis; Despo Ierodiakonou; Konstantinos Vogiatzoglou; Ippokratis Messaritakis; Maria Trypaki; Linda Giannikaki; Maria Sfakianaki; Antonia Kalykaki; Dimitrios Mavroudis; Maria Tzardi; John Souglakos
Journal:  Cancers (Basel)       Date:  2020-04-20       Impact factor: 6.639

4.  Identification of immune-related genes as prognostic factors in bladder cancer.

Authors:  Jie Zhu; Han Wang; Ting Ma; Yan He; Meng Shen; Wei Song; Jing-Jing Wang; Jian-Ping Shi; Meng-Yao Wu; Chao Liu; Wen-Jie Wang; Yue-Qing Huang
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

5.  Pyruvate kinase M2 (PKM2) improve symptoms of post-ischemic stroke depression by activating VEGF to mediate the MAPK/ERK pathway.

Authors:  Yun Feng; Xuebin Li; Jie Wang; Xiaohua Huang; Lanqing Meng; Jianmin Huang
Journal:  Brain Behav       Date:  2021-12-13       Impact factor: 2.708

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.